AR046620A1 - Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende - Google Patents
Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprendeInfo
- Publication number
- AR046620A1 AR046620A1 ARP040104156A ARP040104156A AR046620A1 AR 046620 A1 AR046620 A1 AR 046620A1 AR P040104156 A ARP040104156 A AR P040104156A AR P040104156 A ARP040104156 A AR P040104156A AR 046620 A1 AR046620 A1 AR 046620A1
- Authority
- AR
- Argentina
- Prior art keywords
- zero
- alkyl
- hydrogen
- alkoxy
- substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 2
- 229940126534 drug product Drugs 0.000 title 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 229910052794 bromium Inorganic materials 0.000 abstract 8
- 229910052801 chlorine Inorganic materials 0.000 abstract 8
- 229910052740 iodine Inorganic materials 0.000 abstract 8
- 229910052731 fluorine Inorganic materials 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 206010061216 Infarction Diseases 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 230000007574 infarction Effects 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
Abstract
Son adecuados, por ejemplo, como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto y para el tratamiento de la angina de pecho. También inhiben de forma preventiva los procesos patofisiológicos asociados con el desarrollo de lesiones inducidas por isquemia, especialmente en el desencadenamiento de arritmias cardíacas inducidas por isquemia. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR5R6, -Op-(CH2)n-(CF2)o-CF3 o -(SOm)q-(CH2)r-(CF2)s-CF3; R5 y R6 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; n, o, p, q, r y s son, independientemente uno de otro, cero ó 1; R2 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR7R8, -Ot-(CH2)u-(CF2)v-CF3 o -(SOw)x-(CH2)y-(CF2)z-CF3; R7 y R8 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; t, u, v, w, x, y y z son, independientemente uno de otro, cero ó 1; R3 es Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR9R10, -Oa-(CH2)b-(CF2)c-CF3, -(SOd)e-(CH2)f-(CF2)g-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R9 y R10 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; a, b y c son, independientemente uno de otro, cero ó 1; d es cero, 1 ó 2; e es cero ó 1; f es cero, 1, 2, 3 ó 4; g es cero ó 1; o R3 es -(CH2)h-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Oj-(CH2)k-CF3, alcoxi C1-4, alquilo C1-4, y -SO2CH3; j es cero ó 1; k es cero, 1, 2 ó 3; h es cero, 1, 2, 3 ó 4; o R3 es -(CH2)aa-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Obb-(CH2)cc-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; bb es cero ó 1; cc es cero, 1, 2 ó 3; aa es cero, 1, 2, 3 ó 4; R4 es hidrógeno, F, Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR11R12, -Odd-(CH2)ee-(CF2)ff-CF3, -(SOgg)hh-(CH2)jj-(CF2)kk-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R11 y R12 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; dd, ee y ff son, independientemente uno de otro, cero ó 1; gg es cero, 1 ó 2; hh es cero ó 1; jj es cero, 1, 2, 3 ó 4; kk es cero ó 1; o R4 es -(CH2)ll-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Omm-(CH2)nn-CF3, alcoxi C1-4, alquilo C1-4 y -SO2CH3; mm es cero ó 1; nn es cero, 1, 2 ó 3; ll es cero, 1, 2, 3 ó 4; o R4 es -(CH2)oo-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Opp-(CH2)rr-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; pp es cero ó 1; rr es cero, 1, 2 ó 3; oo es cero, 1, 2, 3 ó 4; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10353202A DE10353202A1 (de) | 2003-11-13 | 2003-11-13 | Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046620A1 true AR046620A1 (es) | 2005-12-14 |
Family
ID=34585094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104156A AR046620A1 (es) | 2003-11-13 | 2004-11-11 | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1685096B1 (es) |
| JP (1) | JP4528304B2 (es) |
| KR (1) | KR101262065B1 (es) |
| CN (1) | CN100445265C (es) |
| AR (1) | AR046620A1 (es) |
| AT (1) | ATE368029T1 (es) |
| AU (1) | AU2004288758B2 (es) |
| BR (1) | BRPI0416487A (es) |
| CA (1) | CA2551057C (es) |
| CR (1) | CR8321A (es) |
| CY (1) | CY1106868T1 (es) |
| DE (2) | DE10353202A1 (es) |
| DK (1) | DK1685096T3 (es) |
| DO (1) | DOP2004001028A (es) |
| EC (1) | ECSP066563A (es) |
| ES (1) | ES2287788T3 (es) |
| GT (1) | GT200400217A (es) |
| HN (1) | HN2004000474A (es) |
| HR (1) | HRP20070364T3 (es) |
| IL (1) | IL175237A (es) |
| JO (1) | JO2466B1 (es) |
| MA (1) | MA28161A1 (es) |
| MY (1) | MY144211A (es) |
| NI (1) | NI200600112A (es) |
| NO (1) | NO20062635L (es) |
| NZ (1) | NZ547172A (es) |
| OA (1) | OA13285A (es) |
| PE (1) | PE20051034A1 (es) |
| PL (1) | PL1685096T3 (es) |
| PT (1) | PT1685096E (es) |
| RS (1) | RS50520B (es) |
| RU (1) | RU2380358C2 (es) |
| TN (1) | TNSN06116A1 (es) |
| TW (1) | TWI334411B (es) |
| UA (1) | UA84307C2 (es) |
| UY (1) | UY28616A1 (es) |
| WO (1) | WO2005047239A1 (es) |
| ZA (1) | ZA200602579B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317124B2 (en) * | 2003-11-13 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates |
| SI2242740T1 (sl) | 2008-02-05 | 2013-03-29 | Sanofi | SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila |
| WO2012094451A1 (en) * | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| WO2015064764A1 (ja) | 2013-11-01 | 2015-05-07 | 宇部興産株式会社 | アリーロイル（オキシ又はアミノ）ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2097409T3 (es) * | 1992-09-22 | 1997-04-01 | Hoechst Ag | Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos. |
| DE4417004A1 (de) * | 1994-05-13 | 1995-11-16 | Hoechst Ag | Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19517848A1 (de) * | 1995-05-16 | 1996-11-21 | Merck Patent Gmbh | Fluorhaltige Benzoylguanidine |
| DE19526381A1 (de) * | 1995-07-19 | 1997-01-23 | Hoechst Ag | 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19713427A1 (de) * | 1997-04-01 | 1998-10-08 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10222192A1 (de) * | 2002-05-18 | 2003-11-27 | Aventis Pharma Gmbh | Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10338554A1 (de) * | 2003-08-22 | 2005-03-31 | Aventis Pharma Deutschland Gmbh | Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
2003
- 2003-11-03 OA OA1200600153A patent/OA13285A/en unknown
- 2003-11-13 DE DE10353202A patent/DE10353202A1/de not_active Withdrawn
-
2004
- 2004-10-06 JO JO2004140A patent/JO2466B1/en active
- 2004-10-27 GT GT200400217A patent/GT200400217A/es unknown
- 2004-11-03 RU RU2006120448/04A patent/RU2380358C2/ru not_active IP Right Cessation
- 2004-11-03 WO PCT/EP2004/012393 patent/WO2005047239A1/de not_active Ceased
- 2004-11-03 DE DE502004004460T patent/DE502004004460D1/de not_active Expired - Lifetime
- 2004-11-03 BR BRPI0416487-3A patent/BRPI0416487A/pt not_active IP Right Cessation
- 2004-11-03 JP JP2006538730A patent/JP4528304B2/ja not_active Expired - Fee Related
- 2004-11-03 DK DK04797535T patent/DK1685096T3/da active
- 2004-11-03 PT PT04797535T patent/PT1685096E/pt unknown
- 2004-11-03 HR HR20070364T patent/HRP20070364T3/xx unknown
- 2004-11-03 CA CA2551057A patent/CA2551057C/en not_active Expired - Fee Related
- 2004-11-03 AT AT04797535T patent/ATE368029T1/de active
- 2004-11-03 NZ NZ547172A patent/NZ547172A/en not_active IP Right Cessation
- 2004-11-03 PL PL04797535T patent/PL1685096T3/pl unknown
- 2004-11-03 UA UAA200606449A patent/UA84307C2/ru unknown
- 2004-11-03 EP EP04797535A patent/EP1685096B1/de not_active Expired - Lifetime
- 2004-11-03 AU AU2004288758A patent/AU2004288758B2/en not_active Ceased
- 2004-11-03 ES ES04797535T patent/ES2287788T3/es not_active Expired - Lifetime
- 2004-11-03 RS RSP-2007/0368A patent/RS50520B/sr unknown
- 2004-11-03 CN CNB200480033483XA patent/CN100445265C/zh not_active Expired - Fee Related
- 2004-11-10 DO DO2004001028A patent/DOP2004001028A/es unknown
- 2004-11-11 AR ARP040104156A patent/AR046620A1/es not_active Application Discontinuation
- 2004-11-11 TW TW093134390A patent/TWI334411B/zh not_active IP Right Cessation
- 2004-11-11 HN HN2004000474A patent/HN2004000474A/es unknown
- 2004-11-12 PE PE2004001110A patent/PE20051034A1/es not_active Application Discontinuation
- 2004-11-12 MY MYPI20044737A patent/MY144211A/en unknown
- 2004-11-12 UY UY28616A patent/UY28616A1/es not_active Application Discontinuation
-
2006
- 2006-03-29 ZA ZA200602579A patent/ZA200602579B/xx unknown
- 2006-03-31 CR CR8321A patent/CR8321A/es unknown
- 2006-04-21 TN TNP2006000116A patent/TNSN06116A1/en unknown
- 2006-04-26 IL IL175237A patent/IL175237A/en not_active IP Right Cessation
- 2006-05-11 EC EC2006006563A patent/ECSP066563A/es unknown
- 2006-05-11 KR KR1020067009186A patent/KR101262065B1/ko not_active Expired - Fee Related
- 2006-05-12 MA MA29028A patent/MA28161A1/fr unknown
- 2006-05-12 NI NI200600112A patent/NI200600112A/es unknown
- 2006-06-08 NO NO20062635A patent/NO20062635L/no unknown
-
2007
- 2007-09-14 CY CY20071101190T patent/CY1106868T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| PE20210050A1 (es) | Nuevos compuestos de sulfonamida carboxamida | |
| AR040201A1 (es) | Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen | |
| CO5580765A2 (es) | Derivados de ciclohexano espirociclicos | |
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| RU2015148010A (ru) | Высокоактивное производное нуклеозида для лечения hcv | |
| AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
| PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| AR074543A1 (es) | Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes | |
| PA8503301A1 (es) | Compuestos para el tratamiento de la isquemia | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| ECSP044999A (es) | Agentes antidiabeticos | |
| CO2021017435A2 (es) | Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
| AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
| AR073844A1 (es) | Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades | |
| UY27835A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
| AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
| AR035196A1 (es) | Derivados de guanidina o biguanidina y el uso de los mismos para la fabricacion de medicamentos antivirales y antimicrobianos | |
| MX2019014216A (es) | Cristal de derivado de heterociclideno acetamida. | |
| AR046620A1 (es) | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende | |
| CY1115377T1 (el) | Παραγωγο αζωτουχου αρωματικου 6-μελους δακτυλιου και φαρμακευτικος παραγων που περιλαμβανει αυτο | |
| MX2021000462A (es) | Derivados de pirrolo-[1,2-b]-piridazina. | |
| AR039401A1 (es) | Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo | |
| ES2115115T3 (es) | Benzoilguanidinas sustituidas con urea, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |